Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07111390). This is a study registration, not published results. Lead sponsor: NYU Langone Health. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 44 participants (ACTUAL). Conditions: Depression, MDD, Major Depressive Disorder, Major Depressive Episode. Interventions: DEVICE: 60Hz Intermittent Light Therapy; DEVICE: Sham Light Therapy. Primary outcome measures: Proportion of Participants who Complete all Scheduled Sessions , Up to Week 3; Average Percentage of Completed Sessions , Up to Week 3; Proportion of Participants who Discontinue due to Adverse Effects , Up to Week 3. Brief summary: This pilot study evaluates the feasibility, safety, and preliminary efficacy of home-based 60Hz intermittent light therapy in adults with a major depressive episode (MDE). Participants will be randomized in a 2:1 ratio to receive either active or sham 60Hz intermittent light stimulation for 30 minutes daily (Monday through Friday) over three weeks. The light is delivered through a wearable headset. Clinical assessments will be conducted remotely at baseline, mid-point, post-treatment, and follow-up to measure changes in depressive symptoms.